Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

UK AAA Endograft trial results look positive

Cook : 14 June, 2007  (New Product)
Cook Aortic Intervention has announced positive findings from the UK elective endovascular aneurysm repair (EVAR) trial.
The trial was led by Professor RM Greenhalgh, head of the Vascular Surgery Research Group at Imperial College, London.

About 15,000 UK residents die each year from AAAs, with the condition being most common in men above the age of 60, and with an increased risk for those with hypertension or peripheral vascular disease.

The EVAR trial generated clinical data used to analyse the secondary intervention rate, aneurysm-related mortality and all-cause mortality for patients receiving EVAR for large abdominal aortic aneurysms using different commercially available endografts.

In the EVAR 1 and 2 multi-centre trials, the principal endografts used were Zenith from Cook and Talent from Medtronic. These are compared in 505 patients from EVAR 1 and 143 patients from EVAR 2 followed up for an average of 3.8 years until 31 December 2005.

Outcomes were analysed by Cox proportional hazards regression, with adjustments for potential confounding risk factors and centre.

Some Gore/Excluder Graft outcomes were also reported, although the device was used in only seven percent of patients.

Across the two trials the secondary intervention rates were 7.0 and 9.4 per 100 patient years for Zenith and Talent grafts respectively, adjusted hazard ratio 0.77 [95 percent CI 0.52-1.12].

Aneurysm-related mortality was 1.2 and 1.4 per 100 patient years for Zenith and Talent grafts respectively, adjusted hazard ratio 0.90 [95 percent CI 0.37-2.19].

All-cause mortality was 8.5 and 10.3 per 100 patient years for Zenith and Talent grafts respectively, adjusted hazard ratio 0.81 [95 percent CI 0.58-1.14].

'The direction of results favours Zenith patients across the reported criteria', comments Barry Thomas, global leader of Cook's Aortic Intervention business division. 'At Cook, we approach medical device creation with the patient in mind'.

'As a result, the Zenith device has become the most-used AAA endograft in the world, a choice these results confirm as being in the best interests of the patient'.

Cook's Zenith AAA Endovascular Graft has regulatory approval for sale in the UK, Canada, Europe, Australia and New Zealand, Japan, Taiwan, and other major markets.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo